Kinfo
Corvus Pharmaceuticals Inc. logo

Corvus Pharmaceuticals Inc.

CRVSNASDAQHealthcare·US · USD
$10.90
-0.03 (-0.27%)
Prices as of October 2, 2026 · market closed

Price

Key statistics

Valuation
Market cap917.34M USD
Enterprise value702.42M USD
Trailing P/E-57.42
Forward P/E-10.21
PEG ratio-0.64
Price / sales0.00
Price / book4.07
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-21.66%
Return on equity-35.43%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-56.85M USD
Net income-54.13M USD
Diluted EPS-$0.64
Rev. growth (YoY)0.00%
Balance sheet
Total cash215.23M USD
Total debt728.00K USD
Debt / equity0.32
Current ratio16.16
Book value / share$2.68
Cash flow (TTM)
Operating cash flow-44.53M USD
Levered free cash flow-27.40M USD
Shares & price
Shares outstanding84.12M
Float72.79M
Held by institutions85.77%
Beta0.86
50-day MA$13.54
200-day MA$14.14
52-week high$26.95
52-week low$6.39
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-06-0.17-0.19−11.76%2026-05-07-0.15-0.15+0.00%2026-03-12-0.13-0.15−15.38%2026-02-121.031.07+3.88%2025-11-04-0.13-0.12+7.69%
About Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer. Corvus Pharmaceuticals Inc. centers its current work on immune modulator product candidates that target pathways involved in immune cell activation, signaling, and function. Its pipeline includes soquelitinib, a lead ITK inhibitor, along with other programs such as anti-CD73, A2AR, A2BR, and anti-CXCR2 approaches. The company’s research spans solid tumors, T-cell lymphomas, autoimmune disorders, allergic conditions, and infectious diseases. Corvus Pharmaceuticals Inc. is positioned in the biotechnology sector as a development-stage company advancing novel drug candidates through clinical evaluation, with a business model built around drug discovery, clinical development, and scientific partnerships.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Richard A. Miller M.D.
Employees
37
Headquarters
South San Francisco, CA, United States

Frequently asked questions about Corvus Pharmaceuticals Inc.